# US 2026/0102439 A1 · Methods for Treating a Health Condition with Probiotics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102439 A1
- Document ID: US20260102439A1
- Status: Published application
- Kind: A1
- Application number: 19/420,278
- Filed: 2025-12-15
- Published: 2026-04-16
- Earliest claimed: 2020-03-18
- Inventors: Sabine Hazan
- Web page: https://patentgrep.com/patent/US20260102439A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 35/745: Bifidobacteria
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/65: Tetracyclines
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 35/24: Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K35/38)
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12Q 1/701: {Specific hybridization probes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of treating a patient with a health condition by administering a probiotic derived from a selected donor. The donor is selected by processing fecal samples from the patient and at least one donor and preparing DNA libraries of their respective microbiomes for comparison. In some aspects, the comparison identifies a donor having a microbiome similar to the patient's baseline microbiome prior to acquiring the health condition. In other aspects, the comparison confirms the donor's microbiome contains at least one bacterium suitable for at least partially restoring the patient's microbiome. The patient is treated by administering a probiotic derived from the selected donor's fecal sample.

## Claims

### Claim 1

A method of treating a patient with a health condition, the method comprising the steps of:
a) acquiring a baseline fecal sample from the patient prior to acquiring the health condition, wherein the baseline fecal sample contains a microbiome of the patient prior to acquiring the health condition;
b) processing the baseline fecal sample from the patient prior to acquiring the health condition by extracting and purifying DNA from the baseline fecal sample of the patient and preparing a DNA library of the microbiome of the patient;
c) acquiring a fecal sample from at least one donor, the fecal sample of the at least one donor containing a microbiome of the at least one donor;
d) processing the fecal sample of the at least one donor by extracting and purifying DNA from the fecal sample of the at least one donor and preparing a DNA library of the microbiome of the at least one donor;
e) comparing the DNA library from the baseline fecal sample of the patient to the DNA library of the at least one donor to determine a matching donor having a DNA library containing a type and amount of bacteria that is more similar to the DNA library of the patient as compared to the DNA library of other donors in the plurality of donors; and
f) after determining the matching donor, treating the health condition by administering to the patient a probiotic derived from the matching donor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fecal samples of the patient and the at least one donor are collected anaerobically.

### Claim 3 (depends on 2)

The method of claim 2, wherein the steps of processing of the fecal samples of the patient and the at least one donor are performed anaerobically.

### Claim 4 (depends on 3)

The method of claim 3, comprising administering one or more of the following to the patient: at least one antibiotic and at least one antiparasitic.

### Claim 5 (depends on 4)

The method of claim 4, wherein the at least one antibiotic is selected from the group consisting of vancomycin, doxycycline, and xiafan.

### Claim 6 (depends on 4)

The method of claim 4, wherein the at least one antiparasitic is ivermectin.

### Claim 7 (depends on 4)

The method of claim 4, wherein the probiotic contains at least one of the following bacteria: Bifidobacterium, Clostridium, Veillonella, Ruminococcus, Faecalibacterium, and Sutterella.

### Claim 8 (depends on 7)

The method of claim 7, wherein the health condition is selected from the group consisting of COVID-19, skin cancer, Clostridioides difficile infection, obesity, Alzheimer's disease, Crohn's disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), psoriasis, chronic urinary tract infections, ulcerative colitis, multiple sclerosis, chronic constipation, Lyme disease, celiac disease, Parkinson's disease, elevated cholesterol, colorectal cancer, amyotrophic lateral sclerosis, fatty liver, rheumatoid arthritis, anxiety, obsessive-compulsive disorder, bipolar disorder, migraine headaches, depression, diabetes mellitus, lupus, epidermolysis bullosa, metastatic mesothelioma, eczema, acne, irritable bowel syndrome, myasthenia gravis, gout, and autism spectrum disorders.

### Claim 9 (depends on 1)

The method of claim 1, comprising administering one or more of the following to patient: at least one antibiotic and at least one antiparasitic.

### Claim 10 (depends on 9)

The method of claim 9, wherein the at least one antibiotic is selected from the group consisting of vancomycin, doxycycline, and xiafan.

### Claim 11 (depends on 9)

The method of claim 9, wherein the at least one antiparasitic is ivermectin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the probiotic contains at least one of the following bacteria: Bifidobacterium, Clostridium, Veillonella, Ruminococcus, Faecalibacterium, and Sutterella.

### Claim 13 (depends on 1)

The method of claim 1, wherein the health condition is selected from the group consisting of COVID-19, skin cancer, Clostridioides difficile infection, obesity, Alzheimer's disease, Crohn's disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), psoriasis, chronic urinary tract infections, ulcerative colitis, multiple sclerosis, chronic constipation, Lyme disease, celiac disease, Parkinson's disease, elevated cholesterol, colorectal cancer, amyotrophic lateral sclerosis, fatty liver, rheumatoid arthritis, anxiety, obsessive-compulsive disorder, bipolar disorder, migraine headaches, depression, diabetes mellitus, lupus, epidermolysis bullosa, metastatic mesothelioma, eczema, acne, irritable bowel syndrome, myasthenia gravis, gout, and autism spectrum disorders.

### Claim 14

A method of treating a patient with a health condition associated with dysbiosis of a gastrointestinal microbiome of the patient, the method comprising the steps of:
a) acquiring a fecal sample from the patient, wherein the fecal sample of the patient contains a microbiome of the patient;
b) processing the fecal sample from the patient by extracting and purifying DNA from the fecal sample of the patient and preparing a DNA library of the microbiome of the patient;
c) acquiring a fecal sample from a donor, wherein the fecal sample from the donor contains a microbiome of the donor;
d) processing the fecal sample from the donor by extracting and purifying DNA from the fecal sample from the donor and preparing a DNA library of the microbiome of the donor;
e) comparing the DNA library of the microbiome of the donor to the DNA library of the microbiome of the patient to confirm the microbiome of the donor contains at least one bacterium suitable for at least partially restoring the microbiome of the patient;
f) selecting the donor based on the confirmation; and
g) treating the patient by administering to the patient a probiotic derived from the fecal sample of the donor, wherein the probiotic restores the gastrointestinal microbiome of the patient to a state prior to the health condition.

### Claim 15 (depends on 14)

The method of claim 14, wherein the probiotic contains at least one of the following bacteria: Bifidobacterium, Clostridium, Veillonella, Ruminococcus, Faecalibacterium, and Sutterella.

### Claim 16 (depends on 14)

The method of claim 14, wherein the fecal samples of the patient and the at least one donor are collected anaerobically.

### Claim 17 (depends on 14)

The method of claim 14, comprising administering one or more of the following to the patient: at least one antibiotic and at least one antiparasitic.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one antibiotic is selected from the group consisting of vancomycin, doxycycline, and xiafan.

### Claim 19 (depends on 17)

The method of claim 17, wherein the at least one antiparasitic is ivermectin.

### Claim 20 (depends on 14)

The method of claim 14, wherein the health condition is selected from the group consisting of COVID-19, skin cancer, Clostridioides difficile infection, obesity, Alzheimer's disease, Crohn's disease, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), psoriasis, chronic urinary tract infections, ulcerative colitis, multiple sclerosis, chronic constipation, Lyme disease, celiac disease, Parkinson's disease, elevated cholesterol, colorectal cancer, amyotrophic lateral sclerosis, fatty liver, rheumatoid arthritis, anxiety, obsessive-compulsive disorder, bipolar disorder, migraine headaches, depression, diabetes mellitus, lupus, epidermolysis bullosa, metastatic mesothelioma, eczema, acne, irritable bowel syndrome, myasthenia gravis, gout, and autism spectrum disorders.
